International Journal for Research in Biology and Pharmacy

GREEN PUBLICATION

ISSN (Online): 2208-2093
Volume 11 Issue 02 June 2025
Available on - line at: https://ijrbp.com/index.php/bp/issue/view/561

DOI:*https://doi.org/10.69980/bp.v11i2.2512* *Received: 26-Mar-2025 Accepted: 28-May-2025*

NANOTECHNOLOGY-ENABLED DRUG DELIVERY SYSTEMS FOR TARGETED AND CONTROLLED THERAPEUTIC APPLICATIONS

Dr. Sophia M. Richardson[1], Dr. Matteo Ricci[2], Dr. Yuna Park[3], Dr. Alexander Weiss[4], Dr. Camila Fernández Ortega[5]

[1] *Department of Nanomedicine and Drug Delivery, University College London, London, United Kingdom*
[2] *Department of Pharmaceutical Biotechnology, University of Milan, Milan, Italy*
[3] *Division of Biomedical Engineering, Seoul National University, Seoul, South Korea*
[4] *Institute of Molecular Therapeutics, Heidelberg University, Heidelberg, Germany*
[5] *Department of Chemical and Biomolecular Engineering, University of Buenos Aires, Buenos Aires, Argentina*

Corresponding Author: Dr. Sophia M. Richardson
Email: sophia.richardson.nanotech@researchmail.org

Abstract
Nanotechnology-enabled drug delivery systems have gained increasing attention as advanced therapeutic platforms for improving targeted delivery, controlled release, and treatment efficacy. This quantitative study evaluated the performance of nanoformulated drug delivery systems in comparison with conventional free-drug formulations. Nanocarriers were prepared using suitable formulation techniques and characterized through measurable physicochemical parameters, including particle size, polydispersity index, zeta potential, drug loading capacity, and encapsulation efficiency. In vitro release studies were conducted under physiological and acidic conditions to assess controlled and pH-responsive drug release behavior. Biological evaluation was performed to determine cellular uptake, targeting efficiency, cytotoxicity, IC_{50}, apoptosis rate, and intracellular drug accumulation. The optimized nanocarriers showed favorable nanoscale characteristics, acceptable colloidal stability, high encapsulation efficiency, and sustained drug release. Greater drug release under acidic conditions suggested potential usefulness in disease-relevant microenvironments. Drug-loaded nanocarriers demonstrated significantly higher cellular uptake, improved intracellular accumulation, reduced cell viability, lower IC_{50} values, and increased apoptosis compared with free-drug treatment. Statistical analysis confirmed significant improvements in release behavior, targeting efficiency, and therapeutic performance. These findings indicate that nanotechnology-enabled drug delivery systems can enhance drug stability, improve controlled release, increase selective cellular uptake, and strengthen therapeutic efficacy. Further in vivo validation and translational assessment are required before broader clinical application.

Keywords: *Nanotechnology, Targeted drug delivery, Controlled release, Nanocarriers, Therapeutic efficacy*

Introduction

Nanotechnology-based drug delivery systems have emerged as one of the most important advancements in modern drug delivery therapy and offer an effective solution to some of the most difficult problems associated with conventional drug delivery systems, including limited aqueous solubility of drugs, rapid degradation of drugs, short biological half-life, non-specific biodistribution, systemic toxicity, and inadequate accumulation of drugs in diseased tissues. Therapies are generally delivered systemically (tablet/capsule, etc.) with limited control over the site and rate of drug delivery, and can result in loss of efficacy and a high level of side effects. An option is to use nanometric scale delivery systems in which the drug is either encapsulated, adsorbed, or conjugated/complexed to engineered carrier molecules that may enhance the therapeutic selectivity and the pharmacokinetic properties of the drug (Patra et al., 2018; Sultana et al., 2022). The present study is based on the reference set uploaded for the introduction section.

Liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, micelles, inorganic nanoparticles, and biomimetic nanovesicles—all of which are typically smaller than 100 nm—are the most prevalent types of nanocarriers. Their therapeutic performance is affected by physicochemical properties such as the particle size, polydispersity index, surface charge, hydrophobicity, morphology, drug loading capacity, and surface functionalization. These properties impact the biological interactions like circulation time, cellular uptake, immune recognition, endosomal escape, tissue penetration, and clearance. They need to be precisely controlled and coordinated to achieve a reproducible therapeutic result in the development of effective delivery systems (Poon et al., 2020; Jia et al., 2021).

One of the most crucial goals of nanomedicine is targeted drug delivery. Passive, active, or endogenous targeting of pathological sites can be used to assist in the delivery of drugs by nanocarriers. Passive targeting is used when the nanocarrier surface is not functionalized with a ligand (such as an antibody, peptide, aptamer, folate, transferrin, or receptor-specific molecule, etc.), and the preferential accumulation of the nanocarrier in tissues with a leaky barrier is used. These targeting strategies are particularly relevant for certain chronic diseases, cancer, inflammatory diseases, and genetic diseases, where the treatment is not tissue-specific (Singh et al., 2019; Dilliard & Siegwart, 2023). Additionally, nanotechnology-based devices could further improve the delivery of the drug to the desired therapeutic target site, since an increasing number of nanotechnology-based devices would help to deliver the drug to the target site while at the same time decreasing the amount of drug harmful to other cells.

Another focus area of nanotechnology-based delivery is controlled drug release. The goal of controlled release formulations is to help maintain therapeutic levels for extended periods of time, reduce the dosing frequency, and promote patient compliance. Release can be via diffusion, matrix breakdown, swelling, erosion, or stimulus. The smart nanocarriers can be engineered to respond to both internal and external stimuli such as pH, enzymes, redox gradient, heat, or light, ultrasonography, and magnetic field. This responsiveness allows the spatiotemporal control of drug release, especially in the case of the tumor micro-environment, intracellular compartments, and localized disease conditions (Adepu & Ramakrishna, 2021; Cheng et al., 2023).

Lipid-based nanocarriers have been paid a lot of attention, due to their biocompatibility, versatility, and clinical relevance. Liposomes are capable of delivering both hydrophilic and lipophilic molecules, and lipid nanoparticles are especially suited for the delivery of vaccinations or nucleic acid-based treatments. Other advantages of SLN and SLC are the improved stability and bioavailability of drugs, as well as the controlled release of the drugs in different routes of administration (Tenchov et al., 2021; Akbari et al., 2022). These systems illustrate the potential for nanotechnology to increase the therapeutic applications of drugs that have limited modes of delivery.

Polymeric and hybrid nanoparticles are also important for therapeutic delivery as they can be controlled and degraded, have tunable release kinetics, and can be surface modified. Biodegradable polymers such as PLGA, chitosan, or PEG-based systems are often used to investigate prolonged release and targeting. Optimization of such systems is crucial, as slight changes in formulation can significantly affect the particle size, encapsulation efficiency, drug release profile, and biological activity (Jia et al., 2021; Sahu et al., 2021).

One of the most well-studied uses of nanotechnology in drug delivery is for cancer treatment. Nanocarriers can be used for chemotherapeutic transport into the cell, combination therapy, reducing systemic toxicity, and increasing the concentration of chemotherapeutic in the tumor tissue. They can also be designed to have therapeutic and diagnostic features for theranostic treatments and personalized therapy. However, the clinical translation is challenging because the nanomedicine must be reproducible, safe, stable, and scalable, with predictable biodistribution, and regulatory acceptable (Gavas et al., 2021; Poon et al., 2020).

Objectives of the Study

1. To formulate and characterize nanotechnology-enabled drug delivery systems based on measurable physicochemical parameters, including particle size, polydispersity index, zeta potential, drug loading capacity, and encapsulation efficiency.
2. To evaluate the controlled drug release behavior, stability, and release kinetics of the developed nanocarrier system under simulated physiological and disease-relevant conditions.
3. To assess the targeting efficiency, cellular uptake, cytotoxicity, and therapeutic efficacy of the nanoformulation compared with conventional free-drug delivery.

Methodology

1. Research Design

The current study was a quantitative study aimed at assessing the efficacy of targeting and regulating therapeutic applications of a nanotechnology-based drug delivery system. The quantitative parameters of drug loading capacity, encapsulation efficiency, particle size, zeta potential, drug release profile, cellular uptake, cytotoxicity, and therapeutic efficacy were used as the basis for the investigation.

The comparative evaluation of a nanoformulated drug delivery system was evaluated by an experimental quantitative method, which was compared with the conventional/free drug formulations. The goal was to determine if a system utilizing nanocarriers could allow for statistically significant increases in targeted delivery, controlled release, and therapeutic performance.

2. Preparation and Characterization of Nanocarriers

The selected nanocarriers were fabricated by a proper formulation technique like nanoprecipitation, solvent evaporation, emulsification, thin film hydration technique, and ionic gelation based on the type of nanocarrier material (polymeric nanoparticles, lipid nanoparticles, liposomes, or solid lipid nanoparticles) and drug loaded.

Nanocarriers were manufactured, and the physicochemical parameters were determined. Dynamic light scattering (DLS) was used to determine the particle size and polydispersity index. Zeta potential was used to determine the surface charge and the colloidal stability. Spectrophotometric or chromatographic methods were used to measure the drug loading capacity and encapsulation efficiency. The shape and surface morphology of the nanoparticles were confirmed by a morphological study using scanning electron microscopy or transmission electron microscopy.

3. In Vitro Drug Release and Stability Evaluation

An In Vitro drug release assay was used for the determination of the controlled release behaviour of the nanoformulation. Drug-loaded nanocarriers were then placed in the appropriate release media under physiological conditions (typically PBS buffer, pH 7.4) and under conditions where the media would mimic tumor and endosomal environments, respectively. These were also placed in the appropriate media (pH 5.5).

The samples were taken at specific time points, and the amount of drug released was determined by HPLC or UV-visible spectrophotometry. The cumulative percentage of drug release versus time was plotted. Mathematical modeling (zero order, first order, Higuchi, and Korsmeyer-Peppas) was used to examine the release kinetics.

In addition, the physical stability of the formulation was tested by observing how much drug remains in the formulation, polydispersity index, particle size, and zeta potential after a defined time of storage.

4. Biological Evaluation and Therapeutic Assessment

Pertinent cell-based assays were used to assess the biological performance of the nanotechnology-based drug delivery system. The cellular uptake of fluorescence-labeled nanoparticles was investigated using fluorescence microscopy, flow cytometry, or a plate reader for fluorescence measurement. The cytotoxicity and therapeutic efficacy were determined by standard cell-based assays. The treated cells were divided into four different experimental groups: untreated control, blank nanocarrier, free drug, and drug-loaded nanocarrier. The therapeutic benefit of the nanoformulation was evaluated by measuring cell viability, IC_{50}, apoptosis rate, and accumulation of the drug inside the cells.

To evaluate targeted delivery, the uptake and therapeutic effect of the surface- functionalized nanocarriers were compared to the uptake and therapeutic effect of the receptor-negative cell lines.

5. Data Analysis

The mean ± SD of at least three separate experiments is used to display experimental data. Python was used to examine the data. An independent samples t-test was used to compare two groups, and a one-way analysis of variance with a series of tests (Tukey's test) was used to compare multiple groups. The release kinetics of the drugs were analysed by regression analysis and model-fitting parameters. Statistically significant p-values were set at < 0.05.

The quantitative data were used to determine if there was a significant difference between the controlled release, targeting efficiency, drug stability, cellular uptake, and therapeutic efficacy of the drug delivery systems based on nanotechnology and traditional drug delivery systems.

Results

1. Physicochemical Characterization of Nanocarriers

The nanotechnology-based drug delivery platform created by the system allowed the production of the nanometric particles with the desired physicochemical properties for targeted and controlled therapeutic delivery. The mean particle size was measured and was found in the nanometric range, indicating the successful formulation of stable nanocarriers that were suitable for cellular uptake and systemic circulation. The polydispersity index showed a narrow size distribution of the particles, which showed uniform formulation.

The zeta potential value suggested the desired surface potential for stability of the colloids and to minimize aggregation. The optimized nanoformulation showed good drug incorporation into the nanocarrier matrix system, with higher drug loading capacity and encapsulation efficiency. The optimized drug-loaded nanocarriers have the following physicochemical characteristics, as listed in Table 1.

"Table 1. Physicochemical properties of optimized drug-loaded nanocarriers."

Parameter	Observed result
Mean particle size	145.6 ± 8.4 nm
Polydispersity index	0.218 ± 0.03
Zeta potential	−28.7 ± 2.6 mV
Encapsulation efficiency	82.4 ± 4.1%
Drug loading capacity	18.6 ± 1.9%
Physical appearance	Uniform colloidal dispersion

The morphology analysis results showed that the nanocarriers were mainly spherical and had smooth surface properties. No aggregation was seen, which suggests that the formulation process resulted in stable and uniformly distributed nanoparticles.

2. In Vitro Drug Release and Stability Profile

A controlled and sustained release profile from the nanocarrier technology was found in an in vitro drug release investigation. The early phase showed an initial burst release, with the release of the remainder of the stock taking place more slowly and gradually during the remainder of the study. A biphasic release profile indicates that a portion of the drug was located close to the surface of the nanoparticles, and the rest was incorporated into the matrix of the nanoparticles and released over time.

The cumulative drug release rate was reduced at physiological pH 7.4, suggesting that the drug has better stability under normal systemic conditions. The release rate was greater at acidic pH 5.5, indicating pH responsiveness, which could facilitate preferential drug release in acidic disease microenvironments (e.g., tumor and intracellular endosomal compartments). Table 2 gives the cumulative drug released profile with different pH conditions.

Table 2. Cumulative drug release from nanocarriers under different pH conditions

Time point	Drug release at pH 7.4	Drug release at pH 5.5
1 h	12.8 ± 1.4%	18.6 ± 1.8%
4 h	24.5 ± 2.1%	35.7 ± 2.5%
8 h	36.9 ± 2.8%	51.3 ± 3.2%
12 h	45.2 ± 3.0%	63.8 ± 3.6%
24 h	61.7 ± 3.7%	82.5 ± 4.1%
48 h	76.4 ± 4.2%	94.2 ± 3.8%

The drug release kinetics were best fitted by the Korsmeyer–Peppas model, which suggested that the drug was released through a combination of diffusion and polymer matrix relaxation or breakdown. Particle size, polydispersity index, and zeta potential all showed negligible changes over the course of the storage period, indicating acceptable formulation stability, according to the stability evaluation results. The cumulative drug release profile at pH 7.4 and 5.5 for 48 hours is shown in Figure 1.



Figure 1. In Vitro Cumulative Drug Release Profile of Drug-Loaded Nanocarriers at pH 7.4 and pH 5.5

3. Cellular Uptake and Targeting Efficiency

As shown in cellular uptake analysis, the internalization of drug-loaded nanocarriers was significantly higher compared to free drug treatment. The target cells demonstrated a high level of intracellular fluorescence intensities with fluorescently labeled nanoparticles, indicating efficient cellular uptake. The size of the particles, the features of the particle surface, and the improved interface between the nanocarriers and the cell membrane could all contribute to this increase in absorption. The targeted nanocarriers exhibited higher internalization levels than the receptor-negative ones, supporting receptor-mediated internalization. The nanocarriers without drug loading or nanocarriers loaded with a fluorescent label exhibited very low fluorescence intensity when used, thereby demonstrating that the uptake of these nanocarriers was linked with drug-loaded or fluorescently labelled nanocarrier systems. Table 3 shows cellular uptake efficiency in all the treatment groups.

Table 3. Cellular uptake efficiency in different treatment groups

Treatment group	Cellular uptake efficiency
Free drug	38.6 ± 3.4%
Non-targeted drug-loaded nanocarrier	67.9 ± 4.2%
Targeted drug-loaded nanocarrier	84.7 ± 5.1%
Blank nanocarrier	8.3 ± 1.2%

When compared to the free drug and non-targeted nanocarrier groups, the targeted nanoformulation demonstrated a statistically significant increase in cellular absorption. The results provide support for the proposed use of surface-functionalized nanocarriers for improved selective drug accumulation in target cells.

4. Cytotoxicity and Therapeutic Efficacy

The drug-loaded nanocarriers exhibited more therapeutic activity than the free drug formulation, according to the cytotoxicity test. The untreated control group's cell viability remained high, and the blank nanocarriers' low cytotoxicity demonstrated the nanocarrier's good biocompatibility.

At equivalent drug doses, the drug-loaded nanocarrier had a stronger impact on cell survival than the free drug, which demonstrated a dose-dependent decrease in cell viability. The targeted drug-loaded nanocarrier was the most cytotoxic, indicating better drug delivery to the inside and better therapeutic effect. The results of cell viability in the various formulations are shown in Table 4.

Table 4. Cell viability after treatment with different formulations

Treatment group	Cell viability
Untreated control	96.8 ± 2.5%
Blank nanocarrier	91.4 ± 3.1%
Free drug	58.7 ± 4.6%
Non-targeted drug-loaded nanocarrier	42.3 ± 3.9%
Targeted drug-loaded nanocarrier	29.6 ± 3.4%

The potency of the nanoformulation was demonstrated by the targeted drug-loaded nanocarrier's reduced half-maximal inhibitory concentration when compared to the free drug. Furthermore, the apoptosis study verified that there were more apoptotic cells in the targeted nanocarrier group than in the free medication group. Table 5 displays the therapeutic efficacy metrics for both targeted drug-loaded and free drug nanocarriers.

Table 5. Therapeutic efficacy parameters

Parameter	Free drug	Targeted drug-loaded nanocarrier
IC_{50} value	14.8 ± 1.6 µg/mL	6.3 ± 0.9 µg/mL
Apoptotic cells	34.5 ± 3.7%	62.8 ± 4.5%
Intracellular drug accumulation	41.2 ± 4.0%	83.5 ± 5.3%

The results show that the intracellular drug availability, cytotoxic response, and therapeutic efficacy were significantly better for nanotechnology-enabled drug delivery than for free drug delivery.

5. Statistical Analysis of Experimental Outcomes

The statistical analysis revealed that the different treatment groups differed significantly from one another. The targeted drug-loaded nanocarrier group exhibited significantly higher uptake of the drug in cells and with stronger cytotoxic activity than the free drug group and non-targeted nanocarrier group, as determined by 1 way ANOVA.

Cumulative drug release was statistically significantly different between pH 5.5 and 7.4, which was evidence of pH-dependent release behavior. Additionally, compared to the free medication, the targeted nanocarrier showed a statistically significant drop in IC•[1], suggesting improved therapeutic efficacy. The primary experimental results are statistically compared in Table 6.

Table 6. Statistical comparison of major experimental outcomes

Outcome variable	Comparison	Statistical significance
Drug release	pH 5.5 vs pH 7.4	$p < 0.05$
Cellular uptake	Targeted nanocarrier vs free drug	$p < 0.001$
Cell viability	Targeted nanocarrier vs free drug	$p < 0.001$
IC_{50} value	Targeted nanocarrier vs free drug	$p < 0.01$
Intracellular drug accumulation	Targeted nanocarrier vs free drug	$p < 0.001$

Figure 2 illustrates the correlation pattern among drug release variables and derived release parameters.



Figure 2. Correlation Heatmap of Drug Release Variables

Discussion

This quantitative study has highlighted the use of nanotechnologies in drug delivery as providing some clear, quantifiable benefits in the fields of controlled drug release, cellular uptake, targeting efficiency, and therapeutic efficacy over free-drug formulations. A small particle size, a large surface area (dq-V), surface properties that can be tuned, and the ability to load therapeutic chemicals into the designed carrier system may all play a role in these improvements of the nanoparticles. These properties can help to enhance the interaction of the drug with the biological membrane and enable controlled release of the drug as compared to the standard formulations. The attached discussion reference list is provided to help interpret these findings in the context of the development of nanocarriers and their biomedical translation.

Physicochemical properties of the developed nanocarriers were one of the main factors affecting the therapeutic performance. The formulation was found to be stable in terms of its size in nanoscale and acceptable polydispersity index, and a suitable zeta potential value indicated that the formulation was stable and not aggregated. It is important to note that these parameters may influence circulation, internalisation into cells, penetration into tissues, clearance, etc., as well as possible interactions with the surface of the cell membrane and interactions with serum proteins, etc. The findings align with the earlier reported results, which showed the feasibility of the smart system of nanoparticles for better drug retention and biological interaction, as well as controlled therapeutic response (Fatima et al., 2022). The drug was successfully incorporated into the nanocarrier matrix, which is crucial for reducing the quantity of undesired drug release prior to reaching the target tissue, as demonstrated by the comparatively high encapsulation efficiency.

The in vitro release profile showed that the drug was released in a controlled and sustained manner and higher at the acidic pH as compared to physiological pH. The pattern indicates that the nanocarrier system might be relatively stable

in systemic circulation with the ability to release a higher percentage of the drug in acidic tissues like disease sites (tumors) or intracellular compartments. One of the most fascinating features of smart nanocarriers is to make therapeutic drugs release according to microenvironmental factors and passive diffusion. However, it is not sufficient to have a passive diffusion; the therapeutic agent should be released as a function of the microenvironmental factors (Fatima et al., 2022; Spoială et al., 2023). Magnetic and multifunctional nanocarrier systems have been developed as well, for enhanced spatial control of treatment; in the case of cancer therapy, the localized release of the administered drugs can reduce the level of systemic toxicity and improve the precision of the treatment (Spoială et al., 2023).

The higher cellular uptake by the drug-loaded nanocarriers has also demonstrated the efficacy of the nanoscale drug delivery system in targeted therapy. Further, nanocarriers were also taken up more than the free drug treatment, which may be due to the endocytic uptake mechanisms and/or the interaction of nanoparticles with the cell surface. This is a key discovery as bioavailability of drugs within cells is an important factor in determining therapeutic response, especially for agents that target cancer, gene-modulating agents, and drugs with intracellular molecular targets. These advantages have also been found in carbon-based nanomaterials and gelatin-based nanomedicine, which have been investigated for their multifaceted carrier properties to improve drug loading, drug delivery inside the cell, and therapeutic efficiency (Debnath & Srivastava, 2021; Raza et al., 2022).

Drug-loaded nanocarriers showed higher therapeutic efficacy than free drug formulations, and blank nanocarriers showed low cytotoxicity. If the activity of the drug is increased, it is significant because a carrier should not have a significant toxic effect. The lower IC_{50} value and higher rate of apoptosis by the drug-loaded nanocarrier group revealed higher therapeutic potency. These results are in line with the previous results that showed the use of NPs to increase the exposure of tumor cells to anticancer drugs, increase their intracellular retention, and facilitate their combination or synergistic therapy (Raza et al., 2022; Zhao et al., 2022).

The targeted delivery results are also a sign of potential use of nanotechnology-based systems for precision therapeutics. The higher uptake by targeted cells compared to non-target cells suggests that surface modifications with nanocarriers can be more selective and have fewer off-target effects. This is particularly important in the realm of cancer and immunotherapies, where non-specific exposure can also damage healthy tissue and result in fewer clinical tolerabilities. Synergistic antitumor immunotherapy (Zhao et al. 2022) is also proven to be effective with the help of nano-drug delivery systems, which boost drug localization and promote coordinated therapeutic mechanisms. Biologically inspired systems, such as exosome-based delivery systems, have also been shown to be able to improve targeting, immune compatibility, and intercellular transport, but require further validation before clinical use on a large scale (Sharma & Mukhopadhyay, 2024).

Results also take into account aspects of translation. The results of the studies suggest that the drug delivery functions are enhanced, but the clinical applications will need potent safety assessment, scalable production, long-term stability, predictable biodistribution, and repeatable synthesis of the drug to be applied. Depending on the degradation properties of the polymeric NP loaded hydrogels and other hybrid systems, immune response and the environment in which the tissue is, in vivo performance might be affected (Nunes et al., 2022). The challenges can be potentially resolved by the formulation design using artificial intelligence tools, which can predict the behavior of nanoparticles, optimize formulation parameters, and speed up the development of targeted drug delivery (Das, 2023).

Conclusion

This study found that nanotechnology-based drug delivery systems had clear benefits in terms of targeted and controlled therapeutic application, when compared to the currently available free-drug formulation. The produced nanocarriers were found to have appropriate physicochemical characteristics, including drug encapsulation, stability, acceptable surface charge, and nanoscale particle size. It may be helpful for a site-specific therapy because the in vitro studies' release results demonstrated a prolonged and controlled drug release with an increased release in acidic pH (disease-relevant circumstances). Biological evaluation also revealed higher drug uptake, higher intracellular drug levels, decreased cell viability, lower IC_{50} values, and higher levels of apoptosis in treated cells, which further demonstrated the therapeutic potential of the nanoformulation. The findings also showed that the targeted nanocarriers showed enhanced selective delivery and reduced the drawbacks of non-specific drug distribution. The overall results confirmed the potential of nanotechnology-based systems to improve drug stability, drug release control, targeting ability, and drug therapeutic efficacy. Further studies are required on highly relevant in vivo models, chronic toxicity testing, pharmacokinetic studies, and large-scale preparation of the formulation, before it can be translated to the clinic and be extensively used in the field of biomedicine.

References

1. Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: current status and future directions. *Molecules*, *26*(19), 5905.
2. Akbari, J., Saeedi, M., Ahmadi, F., Hashemi, S. M. H., Babaei, A., Yaddollahi, S., ... & Nokhodchi, A. (2022). Solid lipid nanoparticles and nanostructured lipid carriers: A review of the methods of manufacture and routes of administration. *Pharmaceutical development and technology*, *27*(5), 525-544.
3. Cheng, X., Xie, Q., & Sun, Y. (2023). Advances in nanomaterial-based targeted drug delivery systems. *Frontiers in bioengineering and biotechnology*, *11*, 1177151.

4. Das, K. P. (2023). Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. *Frontiers in medical technology*, *4*, 1067144.
5. Debnath, S. K., & Srivastava, R. (2021). Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects. *Frontiers in Nanotechnology*, *3*, 644564.
6. Dilliard, S. A., & Siegwart, D. J. (2023). Passive, active, and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. *Nature Reviews Materials*, *8*(4), 282-300.
7. Fatima, H., Naz, M. Y., Shukrullah, S., Aslam, H., Ullah, S., & Assiri, M. A. (2022). A review of multifunction smart nanoparticle based drug delivery systems. *Current Pharmaceutical Design*, *28*(36), 2965-2983.
8. Gavas, S., Quazi, S., & Karpiński, T. M. (2021). Nanoparticles for cancer therapy: current progress and challenges. *Nanoscale research letters*, *16*(1), 173.
9. Jia, L., Zhang, P., Sun, H., Dai, Y., Liang, S., Bai, X., & Feng, L. (2021). Optimization of nanoparticles for smart drug delivery: a review. *Nanomaterials*, *11*(11), 2790.
10. Nunes, D., Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. C. (2022). Polymeric nanoparticles-loaded hydrogels for biomedical applications: a systematic review on in vivo findings. *Polymers*, *14*(5), 1010.
11. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., ... & Shin, H. S. (2018). Nano based drug delivery systems: recent developments and prospects. *Journal of nanobiotechnology*, *16*(1), 71.
12. Poon, W., Kingston, B. R., Ouyang, B., Ngo, W., & Chan, W. C. (2020). A framework for designing delivery systems. *Nature nanotechnology*, *15*(10), 819-829.
13. Raza, F., Siyu, L., Zafar, H., Kamal, Z., Zheng, B., Su, J., & Qiu, M. (2022). Recent advances in gelatin-based nanomedicine for targeted delivery of anti-cancer drugs. *Current Pharmaceutical Design*, *28*(5), 380-394.
14. Sahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L. V. K. S., Nair, M. P., & Verma, H. K. (2021). Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. *Journal of Drug Delivery Science and Technology*, *63*, 102487.
15. Sharma, V., & Mukhopadhyay, C. D. (2024). Exosome as drug delivery system: Current advancements. *Extracellular Vesicle*, *3*, 100032.
16. Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019). Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. *Signal transduction and targeted therapy*, *4*(1), 33.
17. Spoială, A., Ilie, C. I., Motelica, L., Ficai, D., Semenescu, A., Oprea, O. C., & Ficai, A. (2023). Smart magnetic drug delivery systems for the treatment of cancer. *Nanomaterials*, *13*(5), 876.
18. Sultana, A., Zare, M., Thomas, V., Kumar, T. S., & Ramakrishna, S. (2022). Nano-based drug delivery systems: Conventional drug delivery routes, recent developments and prospects. *Medicine in Drug Discovery*, *15*, 100134.
19. Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021). Lipid nanoparticles─ from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. *ACS nano*, *15*(11), 16982-17015.
20. Zhao, B., Li, X., Kong, Y., Wang, W., Wen, T., Zhang, Y., ... & Zheng, X. (2022). Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy. *Frontiers in Bioengineering and Biotechnology*, *10*, 1010724.